Technical Analysis for AMGN - Amgen Inc.

Grade Last Price % Change Price Change
grade B 183.17 -0.49% -0.90
AMGN closed down 0.49 percent on Wednesday, June 26, 2019, on 72 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical AMGN trend table...

Date Alert Name Type % Chg
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
NR7 Range Contraction 0.00%
Overbought Stochastic Strength 0.00%
Down 3 Days in a Row Weakness 0.00%
Overbought Stochastic Strength -0.49%
Jack-in-the-Box Bullish Bullish Swing Setup -0.90%
NR7 Range Contraction -0.90%
Upper Bollinger Band Walk Strength -0.90%
Inside Day Range Contraction -0.90%

Older signals for AMGN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Its principal products include Neulasta and NEUPOGEN to stimulate the production of neutrophils, which is a type of white blood cell that helps the body fight infections; Enbrel, an inhibitor of tumor necrosis factor that plays a role in the body's response to inflammatory diseases; Aranesp and EPOGEN erythropoiesis-stimulating agents that stimulate the production of red blood cells; and XGEVA/Prolia (denosumab) to treat men with castration-resistant prostate cancer at high risk of developing bone metastases. The company also markets other products comprising Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin (TPO) receptor agonist that mimics endogenous TPO, the primary driver of platelet production. In addition, it provides product candidates in mid- to late-stage development in various therapeutic areas comprising oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine, which includes neuroscience. The company markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and wholesale distributors of pharmaceutical products. It has collaborative arrangements with Pfizer Inc.; Glaxo Group Limited; AstraZeneca Plc; Takeda Pharmaceutical Company Limited; and UCB, as well as a strategic alliance with Astellas Pharma Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Medicine Biotechnology Drugs Pharmaceutical Products Healthcare Providers Inflammation Neuroscience Dialysis Inflammatory Diseases Wholesale Distributors Cancer Care Recombinant Proteins Amgen Castration Resistant Prostate Cancer Growth Factors Human Therapeutic Products Thrombopoietin Receptor Agonists
Is AMGN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 1 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 210.19
52 Week Low 166.3
Average Volume 2,954,976
200-Day Moving Average 189.5472
50-Day Moving Average 175.8098
20-Day Moving Average 177.599
10-Day Moving Average 181.884
Average True Range 3.1467
ADX 30.71
+DI 25.9123
-DI 12.8106
Chandelier Exit (Long, 3 ATRs ) 177.6899
Chandelier Exit (Short, 3 ATRs ) 176.1201
Upper Bollinger Band 188.3026
Lower Bollinger Band 166.8954
Percent B (%b) 0.76
BandWidth 12.053671
MACD Line 2.7732
MACD Signal Line 1.7795
MACD Histogram 0.9937
Fundamentals Value
Market Cap 133.66 Billion
Num Shares 730 Million
EPS 10.98
Price-to-Earnings (P/E) Ratio 16.68
Price-to-Sales 5.59
Price-to-Book 4.07
PEG Ratio 3.29
Dividend 4.60
Dividend Yield 2.51%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 186.47
Resistance 3 (R3) 186.69 185.82 185.92
Resistance 2 (R2) 185.82 184.98 185.71 185.74
Resistance 1 (R1) 184.49 184.46 184.06 184.27 185.55
Pivot Point 183.62 183.62 183.40 183.51 183.62
Support 1 (S1) 182.29 182.78 181.86 182.07 180.79
Support 2 (S2) 181.42 182.26 181.31 180.60
Support 3 (S3) 180.09 181.42 180.42
Support 4 (S4) 179.87